AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
about
The MET axis as a therapeutic target.Biomarker development in MET-targeted therapyc-Met as a Target for Personalized TherapyTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaMET molecular mechanisms and therapies in lung cancerA phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastomaPotential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.Molecular targeting of glioblastoma: Drug discovery and therapiesSmall molecule c-Met kinase inhibitors: a review of recent patents.Development of c-MET pathway inhibitors.Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102Immunotherapy of brain cancers: the past, the present, and future directions.Pathway inhibition: emerging molecular targets for treating glioblastoma.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014The role of the c-Met pathway in lung cancer and the potential for targeted therapy.Astrocyte elevated gene-1: a novel target for human glioma therapy.The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.A simple guide screw method for intracranial xenograft studies in mice.Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expressionMolecular imaging of c-Met tyrosine kinase activity.MET as a possible target for non-small-cell lung cancer.c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivoTargeting the Met signaling pathway in renal cancer.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.MET pathway as a therapeutic target.Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Clinical implications of MET gene copy number in lung cancer.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Targeting the MET oncogene in cancer and metastases.Emerging antibody combinations in oncology.The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Targeting the Met pathway in lung cancer.Progress in cancer therapy targeting c-Met signaling pathway.MET: a promising anticancer therapeutic target.Antiangiogenic therapies in glioblastoma multiforme.Emerging new agents for the management of patients with non-small cell lung cancer.
P2860
Q24609682-83C72E8E-3BE7-4DDB-8013-197558F07614Q26751332-1EE57743-E7C5-4EDE-A0E1-8DF54776EC2AQ26775483-380C0D22-43EE-456A-B112-A432A3BBB89FQ26993238-8E50CC80-73B8-4E03-AAC9-2DAB83BF4BEEQ27022941-2C04602A-1C4B-4807-823B-09CDFDA76093Q28272688-1C9A2C59-B279-4EE8-A6AB-35CC008DD4ADQ30427677-052C4D1D-8567-4483-929A-D49CDED495ABQ33652455-E946E950-C538-49E3-8F4A-AA7FCA19F8BFQ33769429-A64EFB8F-46A7-415C-8906-01535EB83C4DQ33807228-06F3BACB-DC2F-4D9C-802E-CDF072595673Q33911283-B88D5382-77BD-477A-9711-1785C0F2F32FQ34094632-964EB9D6-8B04-40A8-B567-5272E20EB96DQ34198905-23F03865-A174-4D6F-978F-1226C1306353Q34293078-393FFBDD-4B0C-4BA5-9CCC-A0B11635D2B3Q34701587-04854B17-97D3-43C7-B947-5FA8A3C8C31EQ35021359-2D44E768-91C7-4E83-B24D-EDDC58C1C8E3Q35136424-4F06A3C8-A7AA-4DB1-B293-7B89CBAF5FBCQ35146937-A8117D5C-BAB8-4632-A6B0-98EC83A2BD5FQ35190515-0CCF3750-BDAE-4DB1-8A39-9088C5AFD330Q35563524-4FAE16ED-C146-4BAE-9762-C340E8252891Q35591156-D0FF99E3-5F0D-468F-B894-815F279DA63AQ35677873-A635C63D-742F-4EF1-A01B-02C0F8872B13Q35691515-0DB6C1BC-A8D4-4BED-A58D-53C7C78559EAQ36660673-02C2DC10-41E6-47FC-8DD9-1B227482980BQ36741686-590A57C0-E1A0-4829-A619-027FAB42FD7EQ37331862-A100B826-0FD6-4840-807B-0F5BFFF0A55FQ37406706-5C4F977F-0A17-48A8-A870-DF07AAF0E316Q37427292-D0FEE9EA-5AC5-444A-9C19-230B12784EB0Q37533648-4A02C404-9630-49F0-8E6B-E4E7E82B1027Q37690299-C051887A-B899-47A4-B18A-54D959D4055DQ37730020-5CCE0DE9-C869-4FF5-A95C-84C2D42AB2FEQ37792116-A6D476DE-706A-4E44-9D5E-1E84C52A7163Q37893414-3843FF50-39A5-4C7D-B984-F7E7F4E0996BQ37950469-E875B153-5391-45C5-9337-0AD6E3675278Q37996468-33EB90F1-409E-45E3-90C5-007AB3552584Q38002473-7BB98804-BB4B-49AE-B461-DB554EE12E2AQ38007133-52917C66-B8C0-422F-94F3-33F5A727A06CQ38008247-83E47E45-BF7D-4270-901A-FCEEF040A33EQ38010802-72D7D5E6-5148-4298-812A-7C4F56B0B36DQ38019977-56D34276-46E0-42C3-8709-F309C9B55DFC
P2860
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
AMG 102, a fully human anti-he ...... U-87 MG cells and xenografts.
@en
type
label
AMG 102, a fully human anti-he ...... U-87 MG cells and xenografts.
@en
prefLabel
AMG 102, a fully human anti-he ...... U-87 MG cells and xenografts.
@en
P2093
P1476
AMG 102, a fully human anti-he ...... U-87 MG cells and xenografts.
@en
P2093
Angela Coxon
H Toni Jun
Richard Kendall
Robert Radinsky
Teresa L Burgess
P304
P356
10.1158/1078-0432.CCR-06-2969
P407
P433
P577
2007-11-01T00:00:00Z